Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Axsome Therapeutics, Inc.

https://axsome.com/

Latest From Axsome Therapeutics, Inc.

Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake

The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.

Clinical Trials Companies

Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’

An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.

Neurology Clinical Trials

Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?

Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.

M & A Deals

Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout

Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register